Apel­lis’ ex­pan­sion plans in­to ALS face road­block

Apel­lis Phar­ma­ceu­ti­cals has stopped the open-la­bel ex­ten­sion por­tion of a clin­i­cal tri­al test­ing its drug pegc­eta­coplan, ap­proved in var­i­ous forms for two oth­er in­di­ca­tions, in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER